PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
-0.01
Net cash position while AXSM shows net debt of 2.39. Joel Greenblatt would examine if this balance sheet advantage creates strategic opportunities.
-5.62
Negative coverage while AXSM shows 20.02. Joel Greenblatt would look for operating improvements and turnaround potential.
0.00
Current ratio below 50% of AXSM's 1.57. Jim Chanos would check for potential working capital crisis.
No Data
No Data available this quarter, please select a different quarter.